- Home
- DMLP vs CVAC Comparison
DMLP vs CVAC Comparison
Compare DMLP & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- CVAC
- Stock Information
- Founded
- DMLP 2003
- CVAC 2000
- Country
- DMLP United States
- CVAC Germany
- Employees
- DMLP N/A
- CVAC N/A
- Industry
- DMLP Oil & Gas Production
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- CVAC Health Care
- Exchange
- DMLP Nasdaq
- CVAC Nasdaq
- Market Cap
- DMLP 1.3B
- CVAC 1.2B
- IPO Year
- DMLP N/A
- CVAC 2020
- Fundamental
- Price
- DMLP $24.20
- CVAC $5.42
- Analyst Decision
- DMLP
- CVAC Hold
- Analyst Count
- DMLP 0
- CVAC 3
- Target Price
- DMLP N/A
- CVAC $6.83
- AVG Volume (30 Days)
- DMLP 145.6K
- CVAC 691.7K
- Earning Date
- DMLP 08-07-2025
- CVAC 09-02-2025
- Dividend Yield
- DMLP 13.30%
- CVAC N/A
- EPS Growth
- DMLP N/A
- CVAC N/A
- EPS
- DMLP 1.71
- CVAC 1.01
- Revenue
- DMLP $161,859,000.00
- CVAC $599,540,810.00
- Revenue This Year
- DMLP N/A
- CVAC N/A
- Revenue Next Year
- DMLP N/A
- CVAC $24.04
- P/E Ratio
- DMLP $14.22
- CVAC $5.39
- Revenue Growth
- DMLP 4.04
- CVAC 675.15
- 52 Week Low
- DMLP $24.01
- CVAC $2.37
- 52 Week High
- DMLP $34.88
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- DMLP 24.01
- CVAC 50.92
- Support Level
- DMLP $24.01
- CVAC $5.45
- Resistance Level
- DMLP $25.25
- CVAC $5.54
- Average True Range (ATR)
- DMLP 0.60
- CVAC 0.05
- MACD
- DMLP -0.17
- CVAC -0.02
- Stochastic Oscillator
- DMLP 5.97
- CVAC 14.29
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.